Biljana Georgievska, Johan Sandin, James Doherty, Anette Mörtberg, Jan Neelissen, Anita Andersson, Susanne Gruber, Yvonne Nilsson, Pär Schött, Per I. Arvidsson, Sven Hellberg, Gunilla Osswald, Stefan Berg, Johanna Fälting and Ratan V. Bhat AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans Journal of Neurochemistry 125
Article first published online: 11 MAR 2013 | DOI: 10.1111/jnc.12203
GSK3β is a key drug discovery target for the treatment of Alzheimer's disease (AD), because of its potential to hyper-phosphorylate tau and contribute to synaptic degeneration. AZD1080, a potent and selective GSK3 inhibitor, inhibits tau phosphorylation and reverses synaptic plasticity deficits in rodents and demonstrates peripheral target engagement in human. Thus, AZD1080 may have disease-modifying and symptomatic treatment potential for AD.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field